{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:49:17Z","timestamp":1792234157769,"version":"4.4.0"},"reference-count":19,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"\n Background:<\/jats:title>\n In RESPONSE\/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV).<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n Report a post hoc pooled RESPONSE\/RESPONSE-2 analysis.<\/jats:p>\n <\/jats:sec>\n \n Design:<\/jats:title>\n RESPONSE\/RESPONSE-2 were randomized, open-label phase III trials. Adults with hydroxyurea-resistant\/intolerant PV were randomized 1:1 to ruxolitinib or BAT; crossover to ruxolitinib was allowed after primary analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n JAK2<\/jats:italic>\n V617F allele burden, hematocrit control, and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) were assessed.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Among 371 patients, mean\n JAK2<\/jats:italic>\n V617F allele burden declined from baseline (ruxolitinib, 66.1%; crossover, 69.5%) through week 208 (41.4%; 37.1%). Significantly more ruxolitinib versus BAT patients achieved hematocrit control at week 28 (62.0% vs 18.2%;\n p<\/jats:italic>\n \u2009<\u20090.0001) and \u2a7e50% reduction in MPN-SAF TSS at week 16 (48.7% vs 18.0%;\n p<\/jats:italic>\n \u2009<\u20090.0001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n Patients receiving ruxolitinib experienced decreased\n JAK2<\/jats:italic>\n V617F allele burden, durable hematocrit control, and better symptom improvements versus BAT, reinforcing ruxolitinib clinical benefit.\n <\/jats:p>\n <\/jats:sec>\n \n Trial registration:<\/jats:title>\n \n RESPONSE:\n https:\/\/clinicaltrials.gov\/study\/NCT01243944<\/jats:ext-link>\n ; RESPONSE-2:\n https:\/\/clinicaltrials.gov\/study\/NCT02038036<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/20406207261425083","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:00:29Z","timestamp":1774335629000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ruxolitinib treatment in patients with polycythemia vera reduces\n JAK2<\/i>\n variant allele frequency and improves symptom burden and hematocrit control"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[{"name":"Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust, Great Maze Pond, London, SE19RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis et Universit\u00e9 Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Hamer-Maansson","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Naim","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d MPN\/ITP\/TTP Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna 40138, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Dipartimento di Oncologia ed Onco-Ematologia, Universit\u00e0 degli Studi di Milano; Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017697"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106809"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090299"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05754-4"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-638593"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00046-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387787"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0700-2"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280"},{"key":"e_1_3_4_14_2","unstructured":"Incyte Corporation. JAKAFI\u00ae (package insert). Wilmington DE: Incyte Corporation 2023."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01935"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_3_4_19_2","article-title":"Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: results from the phase IIIb RESPONSE-2 study","volume":"101","author":"Passamonti F","year":"2016","unstructured":"Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib proves superior to best available therapy in patients with polycythemia vera (PV) and a nonpalpable spleen: results from the phase IIIb RESPONSE-2 study. Haematologica (EHA Annual Meeting Abstracts) 2016; 101(s1): abstract S112.","journal-title":"Haematologica (EHA Annual Meeting Abstracts)"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261425083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261425083","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261425083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:18Z","timestamp":1777591098000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261425083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"alternative-id":["10.1177\/20406207261425083"],"URL":"https:\/\/doi.org\/10.1177\/20406207261425083","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"20406207261425083"}}